Nanoligent
PrivateLast Round
Series A
Oct 6, 2025
Total Funding Raised
$16.59M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nanoligent is a biotechnology company that develops nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanoligent Comparables
Compare Nanoligent with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mainline Biosciences | 78% | |
| Cybrexa Therapeutics | 76% | |
| Polar NanoPharma | 76% |
Nanoligent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 6, 2025 | ||||
| Grant | Jun 19, 2025 | ||||
| Accelerator | Nov 21, 2023 | ||||
| Seed | Sep 27, 2022 | ||||
| Grant | Dec 13, 2018 |
Key People
Founding team and executive leadership
Nanoligent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Inveready | Series A |
| Avanteca Partners | Seed, Series A |
| Clave Capital | Series A |
| Center for Technological Development and Innovation | Series A |
| i&i Prague | Seed |
| Doorway | Seed, Series A |
| Italian Angels for Growth | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors grew 204% MoM.
- Apr 18, 2026
Monthly visitors grew 243% MoM.
Nanoligent Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nanoligent's valuation, stock price, and market status.
Is Nanoligent a public or private company?
Nanoligent is a private company.
What is the current stock price of Nanoligent?
Nanoligent is a private company, so its shares have no public market price. Caplight tracks Nanoligent's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nanoligent worth (valuation)?
Valuation information for Nanoligent is not publicly available.
Can I buy Nanoligent stock?
Nanoligent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nanoligent's last funding round?
Nanoligent's most recent funding round was Series A on October 6, 2025.
Who are the main investors in Nanoligent?
Key investors in Nanoligent include Inveready, i&i Prague.
Will Nanoligent IPO soon?
No public IPO plans have been announced for Nanoligent.
How can I track Nanoligent secondary market activity?
Caplight tracks bids, offers, and trades in Nanoligent's shares on secondary markets.